NCT06717438View on ClinicalTrials.gov

Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS])

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 13, 2025

Primary Completion Date

January 31, 2030

Study Completion Date

January 31, 2030

Conditions
Jordan's SyndromePPP2R5D Neurodevelopmental Disorder
Interventions
DRUG

BPN14770

Capsules for oral administration

DRUG

Placebo

Capsules for oral administration

Trial Locations (3)

60612

Rush University Medical Center, Chicago

98101

Seattle Children's Hospital, Seattle

02115

Boston Children's Hospital, Boston

Sponsors

Lead Sponsor

Shionogi
All Listed Sponsors
lead

Shionogi

INDUSTRY

NCT06717438 - Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS]) | Biotech Hunter | Biotech Hunter